Organogenesis Holdings Inc. reported its financial results for the third quarter of 2025, revealing a net product revenue of $150.5 million, a 31% increase from $115.2 million in the same period last year. The company’s total revenue for the quarter reached $150.9 million, compared to $115.2 million in the prior year. This growth was primarily driven by a significant increase in sales of Advanced Wound Care products, which generated $141.5 million, up from $108.0 million, and Surgical & Sports Medicine products, which rose to $9.0 million from $7.2 million. However, for the nine months ended September 30, 2025, total revenue decreased to $338.6 million from $355.4 million, reflecting a decline in Advanced Wound Care revenue due to market disruptions.
The company reported a net income of $21.6 million for the third quarter, compared to $12.3 million in the same quarter of 2024. This increase in profitability was attributed to improved operational efficiency and a reduction in losses from operations, which amounted to $18.6 million for the nine months ended September 30, 2025, compared to a loss of $11.5 million in the same period last year. Operating expenses for the quarter increased to $130.1 million from $108.9 million, driven by higher selling, general, and administrative costs, which rose to $79.7 million from $71.8 million.
In terms of strategic developments, Organogenesis has been focusing on expanding its product offerings and enhancing its manufacturing capabilities. The company is transitioning its Dermagraft manufacturing to a new facility in Smithfield, Rhode Island, expected to be operational by 2027. Additionally, the company has entered into a licensing agreement with Vivex Biologics to sell its CYGNUS product line, which is anticipated to contribute to future revenue growth. As of September 30, 2025, the company had approximately 221 direct sales representatives and 175 independent agencies, indicating a robust sales force to support its market presence.
Operationally, Organogenesis has seen fluctuations in its customer engagement metrics, with a notable increase in accounts receivable, which rose to $182.2 million from $119.4 million, reflecting a shift in customer buying patterns. The company’s inventory also increased to $39.6 million from $26.2 million, indicating a strategic buildup in anticipation of future sales. The company’s cash and cash equivalents decreased to $63.7 million from $135.6 million, primarily due to cash used in operating activities, which amounted to $49.7 million for the nine months ended September 30, 2025.
Looking ahead, Organogenesis remains cautiously optimistic about its growth trajectory, despite challenges posed by regulatory changes and market conditions. The company is actively preparing for a meeting with the FDA regarding its ReNu product, which aims to address knee osteoarthritis. The outcome of this meeting could significantly impact the company’s future product offerings and revenue potential. Additionally, the company is closely monitoring the implementation of new Medicare coverage determinations that could affect the utilization of its products. Overall, Organogenesis is focused on leveraging its product pipeline and operational efficiencies to navigate the evolving healthcare landscape.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. specializes in regenerative medicine and tissue-based products for advanced wound care, surgical, and sports medicine markets. Its core offerings include skin substitutes, placental allografts, and collagen biomaterials designed to promote healing of chronic and acute wounds. Serving hospitals, clinics, and surgical centers, the company leverages proprietary technologies, FDA-approved biologics, and a broad product pipeline to address growing healthcare needs driven by aging populations and chronic diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.